Subscribe To
KALV / KalVista's Sebetralstat: A Pill Worth Swallowing In HAE
KALV News
By Business Wire
November 2, 2023
KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical compa more_horizontal
By Seeking Alpha
October 1, 2023
KalVista's Sebetralstat: A Pill Worth Swallowing In HAE
KalVista Pharmaceuticals is positioned to disrupt the HAE treatment landscape with its oral therapy, sebetralstat, offering rapid symptom relief and i more_horizontal
By Zacks Investment Research
September 6, 2023
Is KalVista Pharmaceuticals (KALV) Stock Outpacing Its Medical Peers This Year?
Here is how KalVista Pharmaceuticals, Inc. (KALV) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far th more_horizontal
By Business Wire
July 14, 2023
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 US HAEA National Summit
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical compa more_horizontal
By Zacks Investment Research
July 10, 2023
KalVista (KALV) Surges 15% on Update From Angioedema Study
KalVista (KALV) announces a positive update from its late-stage study on its lead product candidate, sebetralstat, in the treatment of hereditary angi more_horizontal
By Business Wire
June 2, 2023
KalVista Pharmaceuticals to Present Data at the 2023 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical compa more_horizontal
By Business Wire
May 23, 2023
KalVista Pharmaceuticals to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day Virtual Conference
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical compa more_horizontal
By Business Wire
April 27, 2023
KalVista Pharmaceuticals to Present Data at the 13th C1-inhibitor Deficiency & Angioedema Workshop
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical compa more_horizontal
